Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Prepaid Assets (2016 - 2025)

Neurocrine Biosciences' Prepaid Assets history spans 16 years, with the latest figure at $170.7 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 251.96% year-over-year to $170.7 million; the TTM value through Dec 2025 reached $170.7 million, up 251.96%, while the annual FY2025 figure was $170.7 million, 251.96% up from the prior year.
  • Prepaid Assets reached $170.7 million in Q4 2025 per NBIX's latest filing, up from $68.2 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $170.7 million in Q4 2025 to a low of $33.8 million in Q1 2021.
  • Average Prepaid Assets over 5 years is $86.4 million, with a median of $88.4 million recorded in 2022.
  • Peak YoY movement for Prepaid Assets: plummeted 50.41% in 2024, then skyrocketed 251.96% in 2025.
  • A 5-year view of Prepaid Assets shows it stood at $45.5 million in 2021, then surged by 73.85% to $79.1 million in 2022, then increased by 23.64% to $97.8 million in 2023, then tumbled by 50.41% to $48.5 million in 2024, then surged by 251.96% to $170.7 million in 2025.
  • Per Business Quant, the three most recent readings for NBIX's Prepaid Assets are $170.7 million (Q4 2025), $68.2 million (Q3 2025), and $120.7 million (Q2 2025).